Skip to content

Author

S. Misale

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract PR010: A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor immunity in preclinical PDAC models

Recent clinical advances using RAS-targeted small-molecule inhibitors, including daraxonrasib, a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, has shown promising responses but are limited in durability for pancreatic ductal adenocarcinoma (PDAC). Preclinical studies indicate that RAS inhibition ca...

Zi-Rui Zhu, Benjamin C. Barrett, Aadi Bhattacharya et al. · 0 citations
Aug 2026

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma.

PERTACs that degrade the KRAS oncoprotein are a promising modality for the treatment of lung adenocarcinomas, and resistance to PROTACs may differ from conventional KRAS inhibitors, suggesting potential strategies for overcoming such resistance.

S. Garcia Borrego, S. Misale · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.